Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Bausch & Lomb Incorporated
Deal Size : $2,500.0 million
Deal Type : Divestment
Novartis Completes Divestment of ‘Front of Eye’ Ophthalmology Assets
Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...
Brand Name : Xiidra
Molecule Type : Small molecule
Upfront Cash : $1,750.0 million
September 29, 2023
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Bausch & Lomb Incorporated
Deal Size : $2,500.0 million
Deal Type : Divestment
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
Details : The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalm...
Brand Name : Xiidra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 11, 2023
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Bausch & Lomb Incorporated
Deal Size : $2,500.0 million
Deal Type : Divestment
Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy
Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...
Brand Name : Xiidra
Molecule Type : Small molecule
Upfront Cash : $1,750.0 million
June 30, 2023
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Bausch & Lomb Incorporated
Deal Size : $2,500.0 million
Deal Type : Divestment
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatmen...
Brand Name : Xiidra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 30, 2022
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?